Seer, Inc.
HealthcareNASDAQ:SEER · NASDAQ Global Select
+$0.02 today
Vol 0.10M · Avg 0.33M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.4%
avg -19.8%
ROIC
-27.7%
avg -20.5%
ROA
-24.9%
avg -18.0%
Analysis
ROA is currently the strongest return metric at -24.9% versus its period average of -18.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Omid C. Farokhzad | Founder, Chief Executive Officer, & Chair of the Board of Directors | $1.21M | — | 57 | $3.35M | 6.09% |
David R. Horn | President,Treasurer & Chief Financial Officer | $744,805.00 | — | 58 | $493,959.00 | 0.90% |
Asim Siddiqui | Senior Vice President of Research & Tech Development | — | — | — | — | — |
Serafim Batzoglou | Chief Data Officer | — | — | — | — | — |
Kenny Ross | Chief Operations & Product Officer | — | — | — | — | — |
Anthony Bazarko | Chief Commercial Officer | — | — | — | $225,000.00 | 0.41% |
Martin Goldberg | Senior Vice President of Product Development | — | — | — | — | — |
Marissa Dixon | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$302,924.98
Net Sentiment
$302,924.98
Net selling
Most Active
Horn David R.
4 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 8 sells worth $302,924.98 over the last 12 months. That adds up to net selling of $302,924.98. Horn David R. was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +402.1% | +16.3% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +402.1% over three years. Forward estimates point to Revenue at +16.3% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.19B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$841.97M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$129.89M
PepGen Inc.
NASDAQ:PEPG
$101.68M
MediciNova, Inc.
NASDAQ:MNOV
$60.54M
Generation Bio Co.
GBIO
$35.98M
Anebulo Pharmaceuticals, Inc.
ANEB
$15.91M
HCW Biologics Inc.
HCWB
$2.67M
Who manages SEER?
Seer, Inc. (SEER) lists 8 active executives. The top listed executive is Asim Siddiqui, Senior Vice President of Research & Tech Development.
Are SEER insiders buying or selling?
Recent insider activity shows net buying of $2.51M.
Explore More
Continue the stock analysis
Jump to another research area for this company.